Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 13, 2026 07:00 ET | Source: Ocugen

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced...
January 12, 2026 06:30 ET | Source: Ocugen

Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in Stargardt disease patients MALVERN, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) --...
January 09, 2026 07:05 ET | Source: uniQure Inc.

uniQure Announces Type A Meeting Scheduled with FDA

LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
January 09, 2026 07:02 ET | Source: Ocugen

Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

MALVERN, Pa., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...
January 07, 2026 09:00 ET | Source: Siren Biotechnology, Inc.

Siren Biotechnology to Showcase Clinical-Stage Momentum at Major 2026 Healthcare Conferences

Siren Biotechnology to Showcase Clinical-Stage Momentum at Major 2026 Healthcare Conferences
January 06, 2026 01:00 ET | Source: EG 427

EG 427’s Clinical Data Showing Sustained Incontinence Episode Reduction with EG110A DNA Therapy Maintained at 6 Months Timepoint

Paris, Jan. 06, 2026 (GLOBE NEWSWIRE) -- 88% reduction in urinary incontinence episodes in patients with neurogenic bladder sustained through 24 weeksGood tolerability maintainedEnrollment and...
January 05, 2026 10:24 ET | Source: Research and Markets

Gene Therapy R&D Market Forecast Report 2025-2035: Focus on Cancer, Rare Diseases, Cardiovascular, Ophthalmic, Haematology, Neurological, Diabetes Mellitus

Dublin, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The "Gene Therapy R&D Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering. Overall world revenue for the Gene Therapy...
December 22, 2025 07:30 ET | Source: Lexeo Therapeutics

Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025 11:54 ET | Source: NeuExcell Therapeutics

NeuExcell Therapeutics Reports Encouraging Clinical Results with World’s First In Situ Conversion Therapy for Malignant Glioma

NeuExcell’s NXL-004, first in situ conversion gene therapy, shows promising safety and efficacy in 11 GBM patients at ESMO Asia 2025
December 10, 2025 09:20 ET | Source: Ocugen

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

MALVERN, Pa., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...